Volume | 4,567,523 |
|
|||||
News | - | ||||||
Day High | 101.76 | Low High |
|||||
Day Low | 100.31 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Novo Nordisk | NVO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
100.98 | 100.31 | 101.76 | 100.40 | 101.84 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
55,023 | 4,567,523 | US$ 101.17 | US$ 462,084,883 | - | 62.41 - 105.69 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:58:29 | 7 | US$ 100.70 | USD |
Novo Nordisk (NVO) Options Flow Summary
Novo Nordisk Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
456.35B | 4.50B | - | 176.95B | 55.53B | 12.35 | 8.22 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Novo Nordisk News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 104.30 | 105.69 | 100.31 | 103.08 | 3,964,753 | -3.30 | -3.16% |
1 Month | 98.74 | 105.69 | 96.00 | 101.11 | 4,816,452 | 2.26 | 2.29% |
3 Months | 97.075 | 105.69 | 86.96 | 97.74 | 4,513,564 | 3.93 | 4.04% |
6 Months | 78.83 | 105.69 | 75.56 | 94.39 | 2,947,565 | 22.17 | 28.12% |
1 Year | 63.08 | 105.69 | 62.41 | 87.75 | 2,185,710 | 37.92 | 60.11% |
3 Years | 33.41 | 105.69 | 33.295 | 67.26 | 1,544,293 | 67.59 | 202.3% |
5 Years | 23.10 | 105.69 | 21.80 | 52.11 | 1,516,995 | 77.90 | 337.23% |
Novo Nordisk Description
Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |